The erbB family of receptor tyrosine kinases, which consists of the epidermal growth factor receptor (EGFr/ erbB1), erbB2 (neu), erbB3 and erbB4, has been shown to be important for both normal development as well as neoplasia. The expression of rat erbB2 was targeted to the basal layer of mouse epidermis with the bovine keratin 5 promoter. Overexpression of wild type rat erbB2 in the basal layer of epidermis led to alopecia, follicular hyperplasia and sebaceous gland enlargement as well as hyperplasia of the interfollicular epidermis. Spontaneous papillomas, some of which converted to squamous cell carcinomas, arose in homozygous erbB2 transgenic mice as early as 6 weeks of age with 490% incidence by 6 months. Analysis of several proliferation/ dierentiation markers indicated that erbB2 overexpression led to epidermal hyperproliferation and a possible delay in epidermal dierentiation. Transgenic mice were also hypersensitive to the proliferative eects of the skin tumor promoter, 12-0-tetradecanoylphorbol-13-acetate (TPA) and were more sensitive to two-stage carcinogenesis. Elevations in EGFr and erbB2 protein as well as erbB2:EGFr and erbB2:erbB3 heterodimers were observed in skin of the erbB2 transgenic mice. Phosphotyrosine levels of the EGFr, erbB2 and erbB3 proteins were also elevated. These results indicate an important role for erbB2 signaling in epidermal growth, development and neoplasia. Oncogene (2000) 19, 4243 ± 4254.
Introduction
A number of receptor tyrosine kinases (RTKs) have been described (Aaronson, 1991; Schlessinger and Ullrich, 1992; Ullrich and Schlessinger, 1990) . Among them is the erbB family of RTKs consisting of the epidermal growth factor receptor (EGFr/erbB1), erbB2 (neu), erbB3 and erbB4 (Carraway and Cantley, 1994; Dougall et al., 1994) . These RTKs have been shown to be important for both normal development as well as in neoplasia (Aaronson, 1991; Gullick, 1991) . Aberrant expression of the EGFr has been observed in various human tumors (Gullick, 1991) and overexpression of the erbB2 gene occurs frequently in a substantial number of breast cancers and correlates with poor patient prognosis (Hynes and Stern, 1994) . Ampli®cation of the erbB2 gene has also been reported in a number of other carcinomas including adenocarcinoma of the salivary gland (Semba et al., 1985) , ovary (Slamon et al., 1989) , stomach (Fukushige et al., 1986; Yokota et al., 1986) , urinary bladder (Wood et al., 1991) and lung (McCann et al., 1990) . Although all of the erbB family members share similarities in primary structure, receptor activation mechanism, and signal transduction pattern, they bind to dierent ligands. EGFr binds to and can be activated by a number of dierent ligands of the EGF family, including EGF, transforming growth factor a (TGFa), heparin binding EGF-like growth factor (HB-EGF), amphiregulin, betacellulin (reviewed in Groenen et al., 1994; Shing et al., 1993) and epiregulin (Toyoda et al., 1995) . The neuregulin subfamily consists of various isoforms of a and b heregulin or neu dierentiation factors (Holmes et al., 1992) , glial growth factor (Marchese et al., 1990) , gp30 (Lupu et al., 1990) , acetylcholine receptorinducing activity (Falls et al., 1993) and sensory and motor neuron-derived factor (Ho et al., 1995) . These ligands bind to erbB3 and erbB4 (Carraway and Cantley, 1994) leading to heterodimerization and activation of erbB2 following transphosphorylation Cohen et al., 1996; Karunagaran et al., 1996; Pinkas-Kramarski et al., 1996) . Recently, betacellulin has also been shown to bind to erbB4 (Riese et al., 1996) . Ligand-dependent activation of the EGFr can also lead to heterodimerization with erbB2, erbB3 and/or erbB4 (Pinkas- Kramarski et al., 1996) . To date no ligand has been identi®ed for erbB2 King et al., 1988; Plowman et al., 1993; Sliwkowski et al., 1994) .
There is considerable evidence that signaling through the EGFr plays an important role during multistage skin carcinogenesis in mice. In previous experiments, we found that topical application of diverse tumor promoters elevated mRNA and protein levels of EGFr ligands such as TGFa (Kiguchi et al., 1995) , amphiregulin and HB-EGF . Furthermore, the expression (mRNA and protein) of the EGFr and EGFr ligands was constitutively elevated in primary papillomas and squamous cell carcinomas generated by an initiation-promotion regimen Rho et al., 1994) . Studies with transgenic mice have shown that overexpression of TGFa in basal or suprabasal epidermal cells can substitute for ras activation and leads to epidermal hyperplasia (Dominey et al., 1993; Jhappan et al., 1994; Vassar and Fuchs, 1991; Vassar et al., 1992; Wang et al., 1994) . In one of these TGFa transgenic mouse models (Jhappan et al., 1994) papillomas developed following initiation with dimethylbenz(a)anthracene (DMBA) indicating that constitutive EGFr signaling could substitute for the promotion stage of multistage skin carcinogenesis. Jorcano and colleagues reported that signaling through the EGFr was signi®cantly reduced in skin keratinocytes of transgenic mice that overexpress a dominant negative mutant of the EGFr (dnEGFr) in epidermis under the control of the bovine keratin 5 (BK5) promoter (Murillas et al., 1995) . These mice are relatively resistant to two-stage carcinogenesis when initiated with DMBA followed by promotion with 12-0-tetradecanoylphorbol-13-acetate (TPA) (J Jorcano, personal communication). Recently, we reported that both EGFr and erbB2 were activated and that there was an increase in the formation of erbB2:EGFr heterodimers in EGF-stimulated mouse keratinocytes, TPA-treated mouse epidermis, and in the epidermis of TGFa transgenic mice in which the expression of human TGFa was targeted to basal keratinocytes using the human keratin 14 (K14) promoter (Xian et al., 1997) . These latter results suggested the possibility that erbB2 may facilitate signaling through the EGFr during early stages of mouse skin carcinogenesis (i.e. tumor promotion).
Previously, transgenic mice were developed in which the constitutive expression of the activated form of rat erbB2 (i.e., the neu oncogene) was targeted to epidermal basal cells using either the K5 (Bol et al., 1998) or K14 (Xie et al., 1998) promoter. Both transgenic lines exhibited a dramatic phenotype characterized by severe epithelial hyperplasia in multiple organs, including the skin, where hyperplasia of the hair follicles was particularly striking. Due to the severity of the phenotype, these mice only survived for a few weeks. More recently, Xie et al. (1999) reported the development of mice in which conditional expression of activated rat erbB2 was controlled by the administration of doxycycline. Following administration of doxycycline in the drinking water, the mice developed epithelial hyperplasia in multiple organs, including the skin. The skin phenotype was characterized by severe hyperplasia of the epidermis and hair follicles. In addition, it was reported that overexpression of the activated rat erbB2 led to upregulation of TGFa and the EGFr in the epidermis. Prenatal expression of activated rat erbB2 resulted in perinatal death and postnatal expression led to rapid wasting and death. In the study reported here, we have generated transgenic mice that overexpress wild type rat erbB2 under the control of the BK5 promoter. These transgenic mice (referred to as BK5.erbB2) exhibit a milder skin phenotype and have a considerably longer life span than the transgenic mice described above in which activated rat erbB2 was expressed constitutively or conditionally. In addition, spontaneous papillomas, capable of converting to squamous cell carcinomas, arise in BK5.erbB2 transgenic mice as early as 6 weeks of age.
Results

Physical characteristics resulting from transgene expression
Three founders were obtained from the BK5.erbB2 construct and used to establish lines. One line, designated BK5.erbB2A had the strongest phenotype and was used for all of the experiments described in the current study. All of the BK5.erbB2 mice generated exhibited a considerably milder phenotype than the BK5.neu* mice that we described previously (Bol et al., 1998) . Bk5.erbB2A transgenic mice, homozygous for the transgene, exhibited a gross phenotype characterized by alopecia and wrinkled skin. To con®rm transgene expression, indirect immuno¯uorescence for erbB2 protein was performed. The presence of the transgene in genomic DNA (PCR analysis not shown) and expression of rat erbB2 protein correlated with obvious physical characteristics in the transgenic mice. Over 90% of the homozygous BK5.erbB2A transgenic mice and approximately 10% of the hemizygous BK5.erbB2A mice developed spontaneous papillomas by 6 months. Papillomas developed in some homozygous transgenic mice as early as 6 weeks of age. The gross appearance of these tumors resembled that of typical exophytic papillomas generated by standard initiation-promotion regimens (Aldaz and Conti, 1989) . Several of these papillomas (approximately 20%) underwent malignant conversion to squamous cell carcinomas. Note that this is likely an underestimate since mice were not aged speci®cally to follow papilloma conversion. Figure 1 shows the histologic features of the papillomas (Figure 1a ,b) and squamous cell carcinomas (Figure 1c,d ) that developed spontaneously in homozygous BK5.erbB2A mice. Transgene expression, as assessed by indirect immunouorescence staining for the erbB2 protein, is shown in Figure 1b ,d. Note the intense immuno¯uorescence in the epithelial component of the tumors. Seven spontaneous papillomas were analyzed for mutations in codons 12, 13, and 61 of Ha-ras; no mutations were found.
In addition to the gross phenotypic characteristics described above, many transgenic mice had excessive skin growth of the nipples, tail, gums, toes and external genitalia (data not shown), and in some cases, papillomas, that later converted to squamous cell carcinomas, appeared in these areas. In addition, verrucous carcinomas frequently developed on the genitalia of older male mice. Survival was compromised in homozygous BK5.erbB2A mice compared to hemizygous and nontransgenic mice. The majority of homozygous BK5.erbB2A mice died between 6 and 12 months of age. Hemizygous BK5.erbB2A transgenic mice had almost the same life expectancy as nontransgenic siblings.
Histological evaluation of skin from BK5.erbB2A transgenic mice Histologic evaluation of skin from both homozygous and hemizygous BK5.erbB2A transgenic mice revealed signi®cant alterations compared to nontransgenic mice. As shown in Figure 2 , sections of skin stained with H&E revealed hyperplasia of both the hair erbB2 transgenic mice K Kiguchi et al follicles and of the interfollicular epidermis with the severity greater in adult homozygous mice compared to hemizygous transgenic mice. Another striking feature of the skin from BK5.erbB2A transgenic mice was a marked enlargement of the sebaceous glands. It is also clear from the section shown in Figure 2c that hair growth is signi®cantly disrupted in homozygous BK5.erbB2A mice leading to the alopecia observed in these mice. Sections stained with BrdU from age-matched adult nontransgenic mice and hemi-and homozygous BK5.erbB2A transgenic mice (7-weeks-old) are shown in Figure 2d Figure 2 Histological analysis of BK5.erbB2A transgenic mice (7-weeks-old) and age-matched nontransgenic mice. H&E stained sections of dorsal skin from (a) a nontransgenic mouse; (b) a BK5.erbB2A hemizygous transgenic mouse; and (c) a BK5.erbB2A homozygous transgenic mouse. BrdU stained sections of dorsal skin from (d) a nontransgenic mouse; (e) a BK5.erbB2A hemizygous transgenic mouse; and (f) a BK5.erbB2A homozygous transgenic mouse *2000 basal cells in the interfollicular epidermis. The LI was signi®cantly higher (P50.001) in the interfollicular epidermis of both hemi-and homozygous transgenic mice compared to the nontransgenic mice (10.2+2.5% for homozygous, 6.2+0.2% for hemizygous and 2.7+0.2% for nontransgenic mice). Also note the presence of cells that stained positive for BrdU among the epithelial cells lining the sebaceous glands. Overall, the skin was markedly thicker in transgenic mice compared to age-matched nontransgenic mice. These results indicate that constitutive expression of erbB2 led to epidermal hyperproliferation.
Localization of erbB family members and transgene expression in skin
The localization and expression of erbB family members in skin from transgenic and nontransgenic mice was determined by indirect immuno¯uorescence staining as shown in Figure 3 . We were not able to detect erbB4 in the epidermis of either transgenic or nontransgenic mice (data not shown) which is consistent with our earlier ®ndings (Xian et al., 1997) . EGFr and erbB2 proteins were expressed primarily in the basal cell layer, hair follicles, and in the epithelial cells of the sebaceous glands in both transgenic (Figure 3b, d) and nontransgenic mice (Figure 3a, c) . ErbB3 appeared to be expressed in all layers of the epidermis, although expression was predominantly in the suprabasal layer. ErbB3 was also expressed in hair follicles but not in sebaceous glands (Figure 3e ,f). The expression of EGFr, erbB2, and erbB3 in the basal compartment of epidermis is consistent with our earlier work showing expression of these erbB family members in mouse keratinocytes cultured in low calcium medium (Xian et al., 1997) . Although the pattern of expression in the skin for these members of the erbB family was consistent in both transgenic and nontransgenic mice, the intensity of erbB2 and EGFr staining was consistently higher in transgenic mouse skin ( Figure 3a for EGFr and d for erbB2). In this regard, thē uorescence intensity for erbB2 staining in cells of Figure 3 Pattern of expression and localization of erbB family members in frozen skin sections from 7-week-old BK5.erbB2A and nontransgenic mice. Immunostain for EGFr in (a) nontransgenic and (b) transgenic mice. Immunostain for erbB2 in (c) nontransgenic and (d) transgenic mice. Immunostain for erbB3 in (e) nontransgenic and (f) transgenic mice. Cy3-conjugated secondary antibodies were used for EGFr and erbB3 and a FITC-conjugated secondary antibody was used for erbB2 erbB2 transgenic mice K Kiguchi et al the basal layer of skin from transgenic mice was always stronger in homozygous mice versus hemizygous mice (not shown) which is consistent with transgene expression in this epidermal compartment. These data indicated that transgene expression correlated with the severity of the skin phenotype shown in Figure 2 . The elevated level of erbB2 and EGFr as determined by immuno¯uorescence (i.e., protein) in transgenic mice was con®rmed by Western blot analysis.
Analysis of differentiation markers in the skin of BK5 erbB2A transgenic mice
To evaluate the eect of constitutively elevated erbB2 expression on epithelial dierentiation in BK5.erbB2A mice, we examined the expression patterns of keratins 1 and 5, (K1, K5) and loricrin in skin sections as previously described (Bol et al., 1997) . During the stepwise process of normal epidermal dierentiation, the basal layer cells are induced to dierentiate into the suprabasal cells and then into granular cells . The expression of K1, K5, and loricrin were used as speci®c markers to distinguish between the suprabasal, basal, and terminally dierentiated granular cell layers, respectively (Lersch and Fuchs, 1988; Nelson and Sun, 1983; Yuspa et al., 1994; Yuspa, 1994) . In addition, the expression of K6 was also examined. Although K6 is normally expressed in the outer root sheath of hair follicles in adult mice, the expression of K6 can be induced in the interfollicular epidermis by wounding or treatment with a proliferative stimulus such as TPA (Mansbridge and Knapp, 1987; Molloy and Laskin, 1987; Toftgard et al., 1985) . Therefore, K6 is thought to be a marker speci®c for proliferating interfollicular epidermal cells. The expression pattern of the various dierentiation markers in the skin is shown in Figure 4 . As expected, K6 was expressed only in the outer root sheath of hair follicles in the nontransgenic mice (7 weeks of age, Figure 4a ). K5 was expressed in the basal layer of the interfollicular epidermis and in the outer root sheath cells of hair follicles (Figure 4c ). K1 was expressed in the suprabasal cells ( Figure 4e ) and loricrin was evident in the granular cells ( Figure  4g ). In comparison, age-matched BK5.erbB2A transgenic mice had signi®cant levels of K6 expression in hyperplastic hair follicles, in some enlarged sebaceous gland cells, and focally in some areas of the interfollicular epidermis (Figure 4b ). K5 expression was not restricted to the basal layer but was observed in all cell layers of the interfollicular epidermis, in the hair follicles and in epithelial cells of the sebaceous glands (Figure 4d ). K1 expression was observed throughout the suprabasal compartment (Figure 4f ). Loricrin expression, as in the nontransgenic mice, was limited to the granular cells (Figure 4h ). The elevation in LI, the expanded expression of K5 in the suprabasal cells of the epidermis and the upregulation of K6 expression in the interfollicular epidermis of the BK5.erbB2A transgenic mice suggest epidermal hyperproliferation. The expanded expression of both K1 and K5 may be related to epidermal hyperproliferation or a possible delayed epidermal dierentiation (or both).
Status of erbB family members in skin of BK5.erbB2A transgenic mice
The microsomal fraction of whole skin was immunoprecipitated with antibodies to EGFr, erbB2, erbB3/ and erbB4 and then analysed by Western blot with antibodies to the same receptors. The results are shown in Figure 5 ; again we were unable to detect erbB4. As expected, the level of erbB2 protein was signi®cantly elevated in BK5.erbB2A transgenic mice compared to nontransgenic mice (Figure 5a) . Interestingly, the level of EGFr protein was also elevated in the skin of transgenic mice (Figure 5a ) con®rming the results of our immuno¯uorescence analyses. In contrast, the level of erbB3 protein was not signi®cantly dierent between transgenic mice and nontransgenic mice. Similar results were obtained in microsomal fractions isolated from the epidermis only (data not shown). To further con®rm and determine the magnitude of the elevations in erbB2 and EGFr, we performed Western blot analyses of lysate of whole skin from homozygous BK5.erbB2A transgenic mice. These analyses showed an elevation of EGFr and erbB2 (4.8-and 8.2-fold, respectively) after normalization to b-actin expression compared to nontransgenic mice (data not shown).
To determine the phosphorylation status of dierent erbB family members, the microsomal fraction of whole skin was immunoprecipitated with antibodies to each protein followed by Western blot analysis with an antibody to phosphotyrosine residues. In Figure 5a it is evident that in the transgenic mice all three of the erbB family proteins that were detected had elevations in the level of phosphotyrosine. When normalized against the amount of protein, there was an approximate 2.5-fold increase in phosphotyrosine content for each erbB family member in the skin of transgenic mice versus nontransgenic mice. Again, similar results were obtained using epidermal microsomal fractions (data not shown).
The increase in tyrosine phosphorylation of the EGFr, erbB2, and erbB3 suggested a consequential increase in heterodimer formation among erbB family members in the skin of transgenic mice. The results of two sets of experiments designed to detect heterodimer formation are shown in Figure 5b . The microsomal fraction of whole skin was again subjected to immunoprecipitation with an antibody to one of the receptors and then analysed by Western blot with an antibody to a dierent receptor. Co-immunoprecipitation of EGFr with erbB2 (or erbB2 with EGFr) and erbB2 with erbB3 (or erbB3 with erbB2) was signi®cantly elevated in transgenic mice compared to nontransgenic mice. Very low levels of erbB3:EGFr heterodimer formation were observed in both transgenic and nontransgenic mice. Similar results were obtained in an experiment using epidermal preparations (data not shown).
Analysis of TPA responsiveness in BK5.erbB2A transgenic mice
To determine the eect of constitutive expression of erbB2 on responsiveness to TPA, BK5.erbB2A transgenic mice received four topical applications of 1.7 nmol TPA over 2 weeks. Twenty-four hours after the last dose of TPA, changes in epidermal thickness Oncogene erbB2 transgenic mice K Kiguchi et al and LI were measured and are summarized in Table 1 . Epidermal thickness values were 1.5 and 1.7-times higher (29.3+2.4 and 34.1+3.3 vs 19.5+2.5 mm, respectively) in hemizygous and homozygous BK5.erb-B2A transgenic mice, respectively, compared with nontransgenic mice. The labeling indices were 1.7 and 2.5-times higher (14.8+1.8 and 20.4+3.3 vs 8.4+1.5 mm, respectively) in hemizygous and homozygous transgenic mice, respectively, compared to nontransgenic mice. The dierences in both epidermal thickness and LI between transgenic and nontransgenic mice were statistically signi®cant (P50.001). Analysis of the absolute changes in epidermal thickness and LI when comparing each genotype with its respective control showed greater increases in the transgenic mice (both hemi-and homozygous). These data indicate that BK5.erbB2A transgenic mice were more sensitive to the proliferative eects of TPA and that the epidermis of homozygous transgenic mice was slightly more sensitive than that of hemizygous transgenic mice.
Responsiveness of BK5.erbB2A mice to two-stage carcinogenesis
To determine the responsiveness of BK5.erbB2A transgenic mice to skin tumor promotion, two groups of hemizygous transgenic and nontransgenic mice were initiated with either acetone (as control) or DMBA (25 nmol). Two weeks after initiation, mice in both groups were promoted with twice-weekly applications of 5 nmol TPA. The experiment was continued for 26 weeks during which time the incidence and multiplicity (average number of papillomas per mouse) of tumors were scored in each group. The results are shown in Figure 6 . Homozygous transgenic mice were not used for this experiment because of their high spontaneous tumor incidence and reduced survival. The incidence of spontaneous tumors (i.e., treated with acetone only) in the hemizygous BK5.erbB2A mice was 8% (average of 0.2 papilloma per mouse) by the end of this experiment. In the groups of mice treated only with TPA, 52% (average of 0.8 papilloma per mouse) of the hemizygous BK5.erbB2A transgenic mice developed papillomas compared to a 12% incidence (0.2 papillomas per mouse) in nontransgenic mice. In addition, BK5.erbB2A transgenic mice initiated with DMBA and promoted with TPA developed tumors faster and also at a slightly higher number compared to nontransgenic mice. The dierences in incidence and tumor multiplicity were signi®cant at selected timepoints (6, 9, and 12 weeks) during the experiment as shown in Figure 1 (w 2 and Mann-Whitney U-tests, respectively; P50.05). Thus, BK5.erbB2A transgenic mice were more sensitive to the initiation-promotion regimen and developed a greater number of papillomas than nontransgenic mice with TPA treatment alone.
Discussion
The present study has further investigated the role of erbB2 and other erbB family members in epidermal growth and neoplasia by targeting expression of rat erbB2 to the basal layer of mouse skin epidermis with the BK5 promoter. The major ®ndings of this study are as follows: (i) overexpression of wild type rat erbB2 in the basal layer of epidermis led to alopecia, follicular hyperplasia, sebaceous gland enlargement, and hyperplasia of the interfollicular epidermis; (ii) spontaneous papillomas (capable of converting to squamous cell carcinomas) arose in homozygous BK5.erbB2A transgenic mice as early as 6 weeks of age (490% incidence by 6 months); (iii) skin of BK5.erbB2A transgenic mice exhibited epidermal hyperproliferation and a possible delay in epidermal dierentiation; (iv) BK5.erbB2A transgenic mice were hypersensitive to the proliferative eects of the skin tumor promoter, TPA, and developed papillomas with TPA treatment alone. BK5.erbB2A transgenic mice were also more sensitive to two-stage carcinogenesis; and (v) elevations in EGFr and erbB2 proteins as well as elevations in erbB2:EGFr and erbB2:erbB3 heterodimers were observed in the Figure 5 Western blot analysis of erbB family members in the skin of BK5.erbB2A transgenic mice. The microsomal fraction of whole skin was immunoprecipitated with antibodies to EGFr, erbB2 and erbB3 and then analysed by Western blot with the respective antibodies. The microsomal fraction was also immunoprecipitated with antibodies to these receptors followed by Western blotting with the phosphotyrosine speci®c antibody PY20. (a) EGFr, erbB2, and erbB3 levels and phosphorylation status in whole skin lysate from nontransgenic (NTg) and BK5.erbB2A (Tg) mice. (b) Western blot analysis of heterodimer formation of erbB family members in the skin of BK5.erbB2A transgenic mice. The microsomal fractions of whole skin were immunoprecipitated with an antibody to one of the receptors and then analysed by Western blot with an antibody to a dierent receptor skin of BK5.erbB2A mice. Correspondingly, phosphotyrosine levels of the EGFr, erbB2, and erbB3 proteins were elevated in skin of the transgenic mice. Taken together, the current results provide further support for an important role of erbB2 signaling in both epidermal growth and development as well as in epidermal neoplasia.
In our previous work with BK5.neu* transgenic mice (i.e., transgenic mice overexpressing activated erbB2), we reported that founder mice developed a sparse hair coat and had thickened skin (Bol et al., 1998) . Histologic analysis of these mice revealed a dramatic skin phenotype characterized by marked follicular hyperplasia encompassing a signi®cant portion of the dermis. Hyperplasia of the interfollicular epidermis was also observed. The BK5.neu* founders all died by 3 weeks of age, by which point one founder had already developed two spontaneous papillomas. The results obtained with these BK5.neu* founders provided strong support for an important role of erbB2 signaling in the control of cell proliferation in epidermis as well as in the development of skin tumors. Xie et al. (1998) reported the development of transgenic mice in which activated rat c-neu/erbB2 was expressed under the control of the human K14 promoter. Transgenic founder mice exhibited dramatic disruption in hair follicle morphogenesis similar to BK5.neu* mice. The majority of the hair follicles were replaced by hyperproliferative intradermal squamous invagination. All but one of these transgenic founder mice also died before or shortly after birth. One founder mouse thought to be chimeric lived longer and developed papillomas on the ears and tail by 3 months of age. Interestingly, founders in both transgenic models in which activated erbB2 was overexpressed exhibited severe hyperplasia in the esophagus that may have contributed to the rapid postnatal wasting observed (Bol et al., 1998; Xie et al., 1998) . Xie et al. (1999) also developed a K14-rtTA/TetRE-erbB2`Tet-On' bitransgenic mouse system in which the expression of the activated c-neu/erbB2 was induced by doxycycline. These mice were phenotypically normal until exposure to doxycycline induced transgene expression. Although the induction of the transgene was rapid and reversible over a short period, more prolonged induction of activated erbB2 caused hyperplasia in epithelial tissues such as skin, cornea, tongue, and esophagus. Regardless of the time of administration (i.e., pre-or postnatally) these animals died within a short period if exposure to doxycycline was prolonged. The BK5.erbB2A mice developed in our current study appear to oer several advantages over the previously developed transgenic mice using activated erbB2. First, the use of a non-activated form of erbB2 (i.e., wild-type rat erbB2) led to a milder phenotype. Second, although the average life span of mice homozygous for the BK5.erbB2 transgene was less than a year, the life span of hemizygous mice was comparable to that of nontransgenic mice, allowing one to evaluate the role of erbB2 signaling in neoplasia. A particularly signi®cant ®nding in the current study was the development of spontaneous skin papillomas (capable of converting to squamous cell carcinomas) in 490% of homozygous BK5.erbB2A transgenic mice by 6 months of age. Finally, the use of a non-activated form of erbB2 may better reproduce what occurs in many human tumors where endogenous erbB2 is overexpressed.
Signaling through the constitutively elevated wildtype erbB2 mediated eects on both epidermal proliferation and possibly dierentiation in BK5.erb-B2A mice. We found that in these mice, K1, K5, K6 and loricrin were simultaneously expressed in the outermost layers of epidermis. In both of the transgenic models described by Xie and colleagues (Xie et al., 1998 (Xie et al., , 1999 in which the expression of activated rat c-neu/erbB2 is under the control of the K14 promoter, there is simultaneous expression of K14, K10, and K16 in the outermost layers of the epidermis. Keratins 14, 10, and 16 are also used as and Mann ± Whitney test, respectively, P50.05) at selected timepoints (indicated by *). Weeks 6, 9, and 12 were selected for both tumor incidence and multiplicity for statistical analyses. The average numbers of papillomas per mouse (+s.d.) for transgenic and nontransgenic mice at these timepoints were 1.2+0.3 and 0 at week 6, 4.0+2.12 and 1.8+0.4 at week 9, and 6.2+0.6 and 4.1+0.5 at week 12, respectively erbB2 transgenic mice K Kiguchi et al markers to distinguish between basal cells, suprabasal cells and proliferative cells, respectively (Lersch and Fuchs, 1998; Nelson and Sun, 1983; Yuspa, 1994) . In both of these K14 transgenic models, the expression of ®laggrin (which is a terminal dierentiation marker similar to loricrin) and K10 was signi®cantly reduced in the suprabasal cell layer, a further indication that the process of dierentiation was altered in the epidermis of these mice. Endogenous K14 was expressed not only in the uppermost two or three layers of epidermis but also in areas of intradermal squamous growth. In our BK5.neu* mice, K6 was also expressed in the interfollicular epidermis, hair follicles and in epidermal cells (presumably hair follicle-derived) invading the hypodermis (Bol et al., 1998) . Thus, the results from both the BK5.erbB2A and BK5.neu* mice as well as both of the activated erbB2 transgenic models suggest that overexpression of either wild-type erbB2 or activated erbB2 (neu*) induces epidermal hyperproliferation accompanied by defects in the process of epithelial dierentiation. In the BK5.erbB2A transgenic mice K1, K5, K6, and loricrin were expressed simultaneously in the outermost layers of the epidermis, however, only the pattern of the expression of loricrin was normal. In addition, K6 expression was observed only focally in the interfollicular epidermis. These results suggest that elevated expression of wild-type erbB2 may have impeded terminal dierentiation in the epidermis of BK5.erb-B2A mice but these eects were clearly milder than those observed in mice overexpressing activated forms of erbB2 in epidermal basal cells. To determine the mechanism for the observed phenotype in the skin of BK5.erbB2A transgenic mice we examined the status of erbB family members. Western blot analysis demonstrated that three erbB family members (EGFr, erbB2, and erbB3) were expressed in whole skin and epidermis from both nontransgenic mice and BK5.erbB2A transgenic mice. We were unable to detect erbB4 in whole skin and epidermis from either nontransgenic or transgenic mice which is consistent with our earlier ®ndings (Xian et al., 1997) . Immunoprecipitation with antibodies to each of the erbB members followed by Western blotting with the same antibodies or with an antibody to phosphotyrosine residues showed that BK5.erbB2A transgenic mice exhibited: (i) elevated erbB2 protein as expected compared to nontransgenic mice; (ii) elevated EGFr protein levels; and (iii) elevated phosphotyrosine levels of EGFr, erbB2, and erbB3. Furthermore, elevated heterodimer formation between erbB2 and both the EGFr and erbB3 was detected. Thus, the skin phenotype in BK5.erbB2A mice may arise via elevated signaling through erbB2:erbB2 homodimers and/or erbB2:EGFr and erbB2:erbB3 heterodimers.
The mechanism for elevated heterodimer formation and increased phosphorylation of erbB family members in BK5.erbB2A transgenic mice is unknown at present. However, several possible mechanisms may be operating. First, elevated levels of erbB2 protein on the surface of epidermal basal cells may increase the likelihood of a physical interaction between other erbB family members also expressed in these cells. In this case, there may be sucient ligand around to facilitate increased heterodimer formation and activation or the physical interaction alone may stimulate transphosphorylation and activation. Second, there may be alterations in the levels of ligands present. In this regard, we previously reported that stimulation of cultured mouse keratinocytes with EGF led to hyperphosphorylation of both EGFr and erbB2 (Xian et al., 1997) . In addition, increased heterodimer formation was observed. In mouse epidermis, treatment with TPA or overexpression of TGFa led to hyperphosphorylation of EGFr and erbB2 presumably through a similar mechanism (Xian et al., 1997) . Xie et al. (1999) reported increased TGFa and EGFr mRNA levels in epidermis after induction of activated erbB2 in conditional transgenic mice by doxycycline. Thus, in BK5.erbB2A transgenic mice the constitutive elevation of wild-type erbB2 may lead to elevated levels of EGFr ligands causing a subsequent increase in the formation of EGFr:erbB2 heterodimers. However, we have not detected an increase in the level of TGFa mRNA in the epidermis of BK5.erbB2A mice either by semiquantitative RT ± PCR or Northern analysis (data not shown), although as shown in Figure 5 , EGFr protein levels are elevated. The mechanism for increased EGFr was brie¯y explored (data not shown). Semiquantitative RT ± PCR revealed that the level of EGFr mRNA was elevated in epidermis of BK5.erbB2A transgenic mice. This ®nding is consistent with the data reported by Xie et al. (1999) . However, since EGFr:erbB2 heterodimer formation was elevated in the epidermis of BK5.erbB2A transgenic mice we cannot rule out the possibility that the increase in EGFr:erbB2 heterodimers may have reduced the rate or extent of endocytosis thereby also contributing to increased EGFr levels (Wang et al., 1999) .
The fact that constitutive expression of erbB2 leads to an increase in erbB2:erbB3 heterodimer formation and an increase in erbB3 tyrosine phosphorylation raises the interesting possibility that erbB2:erbB3 heterodimers may also contribute to the phenotype in BK5.erbB2A mice. In our previous experiments, in which mouse keratinocytes were exposed to EGF, we did not see any alterations in erbB3 phosphorylation. Therefore, it is unlikely that erbB3 becomes hyperphosphorylated as a result of EGFr activation. This conclusion is further supported by the low level of EGFr:erbB3 heterodimer formation in the skin of BK5.erbB2A transgenic mice. The analysis of the distribution of erbB family members in skin shown in Figure 3 indicates that erbB2 and erbB3 have overlapping expression in the basal layer although erbB3 was also localized in the more dierentiated layers of the epidermis. These data indicate that functional erbB2:erbB3 heterodimers could form in epidermal basal cells. Thus, overexpression of erbB2 in BK5.erb-B2A mice may stimulate formation of functional erbB2:erbB3 heterodimers and subsequent signal transduction.
As part of the current study, we found that the skin of BK5.erbB2A transgenic mice was hypersensitive to the tumor promoter TPA (Table 1 ). This was re¯ected in both markers of TPA-induced epidermal cell proliferation (i.e., hyperplasia and LI). These data suggested that BK5.erbB2A mice may be more sensitive to the tumor promotion stage of two-stage chemical carcinogenesis in mouse skin. This hypothesis was tested and con®rmed by performing a two-stage skin carcinogenesis experiment. The results of this experiment showed that papillomas arose earlier and faster in skin of hemizygous BK5.erbB2A transgenic mice initiated with DMBA and promoted with TPA compared to nontransgenic mice. The number of papillomas was also higher in these mice (Figure 6 ). In addition, treatment of non-initiated BK5.erbB2A transgenic mice with TPA alone led to the formation of skin papillomas. These data, taken together with the fact that spontaneous tumors developed in the absence of any treatment, suggest that overexpression of erbB2 in BK5.erbB2A transgenic mice provided both an initiating and promoting stimulus.
In conclusion, overexpression of wild-type erbB2 in epidermal basal cells of mouse skin leads to a characteristic phenotype, i.e., alopecia, hyperplasia of follicular and interfollicular epidermis, and sebaceous gland enlargement. In addition, overexpression of erbB2 in epidermal basal cells delayed epidermal dierentiation and led to epidermal hyperproliferation. Spontaneous papillomas (capable of converting to squamous cell carcinomas) arose in homozygous BK5.erbB2A transgenic mice as early as 6 weeks of age (490% incidence by 6 months). The current data, in conjunction with earlier studies, indicate an important role for erbB2 in regulating epidermal growth as well as neoplasia in this tissue. Thus, the BK5.erbB2A transgenic mice represent a unique new animal model for further mechanistic studies involving the role of erbB2 in epithelial growth and neoplasia.
Materials and methods
Preparation of the DNA construct
To target expression of erbB2 to epidermal basal cells, the 4.7 Kb rat erbB2 cDNA insert was excised from the parent vector pSV-erbB2 (a gift from Dr Mien-Chie Hung, UT MD Anderson Cancer Center) (Kiyokawa et al., 1995) with restriction enzymes HindIII and SalI and inserted into the 7Kb BK5 keratinocyte expression vector described previously (Bol et al., 1998) . Rat erbB2 is over 90% homologous to mouse erbB2 cDNA. Orientation and integrity of the cDNA insert was determined by a series of diagnostic restriction digests. The resulting 12 Kb construct contained the BK5 promoter for transcription of the rabbit b-globin intron, the neu cDNA, and a SV40 polyadenylation signal.
Plasmid DNA was prepared by standard techniques (Sambrook et al., 1994) . pBK5.erbB2 was digested with KpnI to release the vector sequences from the expression construct, and the two fragments separated by electrophoresis through a 0.8% agarose gel. The larger fragment containing the expression construct was isolated from a gel slice and the DNA puri®ed using the Prepagene DNA cleanup kit (BioRad, Hercules, CA, USA).
Generation and identification of transgenic mice
Donor embryos for injection were generated through a mating of FVB male mice (National Cancer Institute, Research Facility, Frederick, MD, USA) to superovulated ICR female mice (Harlan Sprague Dawley, Indianapolis, IN, USA) and were isolated as described (Hogan et al., 1994) . DNA was injected into the pronucleus of these F 1 embryos, and survivors were transferred to pseudopregnant ICR females. Transgenic animals were identi®ed by PCR of DNA isolated from the tails of weanlings (Miller et al., 1988) using oligonucleotides speci®c for the rabbit b-globin cDNA.
Analysis of transgene expression
The expression and localization of the transgene as well as the expression of endogenous mouse erbB2 were determined using immuno¯uorescence on sections of dorsal skins and skin tumors. The tissues were ®xed in formalin, embedded in paran and 4 mm sections were adhered to slides. After deparanization, the slides were microwaved twice for 5 min to enhance the staining of erbB2. Sections were incubated with 10% non-immunized goat serum for 30 min to block the non-speci®c Fc-receptor in tissue and then washed three times with phosphate-buered saline, pH 7.5, containing 0.1% bovine serum albumin (BSA/PBS). Sections were then incubated with either a 1 : 300 dilution of the primary rabbit polyclonal antibody against the epitope corresponding to amino acids 1169 ± 1186 mapping to the carboxy terminus of the precursor forms of human neu gp 185 (C-18) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) in BSA/PBS, or pre-immune rabbit serum as a negative control for 40 min. Following three washes with BSA/PBS, the sections were incubated with the secondary¯uorescence (FITC)-conjugated anity puri®ed F(ab') 2 fragment of goat anti-rabbit IgG (1 : 200; Jackson Immuno Research Lab, West Grove, PA, USA) for 40 min. The sections were then covered with Vectashield mounting solution (Vector Laboratories Inc., Burlingame, CA, USA) before the cover slips were attached. Immunospeci®city of erbB2 IgG was con®rmed by preabsorption with the antigen.
Localization of erbB family receptors in mouse skin
Frozen sections of mouse skin (10 mm) were incubated with either C-18 (1 : 150), or rabbit polyclonal antibody against the epitope corresponding to the carboxy terminus of the precursor form of the EGF receptor of human origin (SC-03, 1 : 150; Santa Cruz Biotechnology, Inc.), rabbit polyclonal antibody against the carboxyl terminus of the precursor form of erbB3 p160 of human origin (1 : 250), or preimmune rabbit serum as negative control, overnight at 48C. Following three washes with BSA/PBS, the sections were incubated with the secondary Cy3-conjugated or FITC-conjugated anity puri®ed F(ab') 2 fragment of goat anti-rabbit IgG (1 : 200; Jackson Immuno Research Lab). Immunospeci®city was con®rmed by preabsorption with each antigen. The sections were mounted in Vectashield and localization of each protein was visualized by a Fluoroview Laser Confocal Microscope (Olympus Optical Co., Melville, NY, USA).
Histological analyses
Dorsal skin samples and tumors were ®xed in either formalin or ethanol and embedded in paran prior to sectioning. Sections of 4 mm were cut and stained with hematoxylin-eosin (H&E). Mice were injected i.p. with bromodeoxyuridine (BrdU) in PBS (100 mg/g body weight) 30 min prior to sacri®ce. For the analysis of epidermal labeling index (LI), paran sections were stained using anti-BrdU antibody as previously described (Eldridge et al., 1990) . The LI is calculated by determining the per cent of labeled basal cells from observing *2000 interfollicular epidermal basal cells. The determinations of epidermal thickness and LI were performed as previously described (Naito et al., 1987) . For the analyses of the expression of keratins 1, 5, and 6, and loricrin, tissues were ®xed in ethanol and immunostained as previously described (Bol et al., 1997) .
In vivo sample preparation and immunoprecipitation
Mice were killed by cervical dislocation, and dorsal skins treated with a depilatory agent (41 min). The skin was excised and epidermal tissue was scraped o with a razor blade into lysate buer (50 mM Tris-HCl, pH 7.4, 1% NP-40, erbB2 transgenic mice K Kiguchi et al 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 0.7 mg/ml aprotinin, 0.5 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM Na 3 VO 4 and 1 mM NaF). Whole skin was snap frozen in liquid N 2 , ground with a mortar and pestle, and homogenized with a 3cc syringe through an 18 G needle. The homogenate was centrifuged at 14 000 g for 15 min at 48C and the supernatant was pre-incubated with protein A-agarose beads for 10 min at 48C. The resulting cleared supernatant was then immunoprecipitated with antibody for 2 h, followed by a second incubation with protein A agarose for 1 h. The immunocomplex was precipitated by brief centrifugation and subjected to SDS ± PAGE.
Western blot analysis
Whole cell lysate and the immunoprecipitates were electrophoresed through 7 ± 10% SDS/polyacrylamide gels according to the method of Laemmli 1970) under reducing conditions. Separated proteins were electrophoretically transferred onto polyvinylidene membranes. After blocking with 1% nonfat powdered milk in TTBS (0.5 M NaCl, 20 mM Tris, pH 7.5, 0.05% Tween), the receptor protein levels of EGFr, erbB2, and erbB3 were detected by incubating the membrane with the corresponding anti-erbB antibodies (1 : 1000; Santa Cruz Biotechnology, Inc.). Phosphotyrosine levels of the immunoprecipitates were detected using the antiphosphotyrosine antibody PY20 (Transduction Laboratories, Lexington, KY, USA). Protein bands were visualized using enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech, Piscataway, NJ, USA). The relative dierences between control and treated samples were quantitated by densitometry using a Visage 60 analyzer (BioImage, Millipore Corporation, Bedford, MA, USA).
Tumor induction experiment
Hemizygous BK5.erbB2 transgenic mice (7 ± 15 weeks of age), along with age-matched littermate controls, were shaved 2 days prior to initiation. Mice were initiated with a single topical application of 25 nmol DMBA in 0.2 ml of acetone. Two weeks later, promotion was started by topical application of 5 nmol TPA in 0.2 ml acetone twice a week for 26 weeks. Individual groups of both transgenic and control mice received treatment regimens of either acetone/ TPA or DMBA/TPA. Mice were examined weekly for the presence of papillomas. Tumor multiplicity (papillomas per mouse) and tumor incidence were recorded weekly.
Analysis of Ha-ras mutations
Seven spontaneous papillomas from BK5.erbB2 mice were analysed for mutations in the Ha-ras gene. Genomic DNA isolated from mouse skin papillomas was used to amplify a region containing Ha-ras codons 12, 13, and 61 as previously described (DiGiovanni et al., 2000) . The PCR products were then sequenced for mutations in all three codons.
